サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1378847

ファーマジング市場：世界の産業動向、シェア、規模、成長、機会、2023-2028年予測

Pharmerging Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
出版日: | 発行: IMARC | ページ情報: 英文 149 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.53円
ファーマジング市場：世界の産業動向、シェア、規模、成長、機会、2023-2028年予測
出版日: 2023年11月02日
発行: IMARC
ページ情報: 英文 149 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

概要

世界のファーマジング市場規模は2022年に11億米ドルに達しました。IMARC Groupは、2022年から2028年にかけて12.2%の成長率（CAGR）を示し、2028年には22億米ドルに達すると予測しています。

製薬新興国とは、医薬品市場における地位は低いもの、急速に成長している国々を指します。主な新興医薬品市場には、中国、インド、ブラジル、ロシア、南アフリカ、メキシコ、インドネシア、トルコなどがあります。

私立病院の増加とともにヘルスケア支出が増加していることが、現在世界の医薬品新興市場の成長を後押ししています。さらに、多くの慢性疾患の高い有病率と、疾患の早期発見と治療手順に対する消費者の意識の高まりが、市場の成長をさらに増大させています。さらに、認知症、高血圧、心不全などの深刻な病状に陥りやすい老年人口の増加も、医薬品需要を押し上げています。さらに、慢性疾患の治療費削減を目的とした各国政府の政策や償還制度の導入も、市場の成長を後押ししています。さらに、医薬品新興国では、自己負担額を減らすために多くの保険を提供する保険会社が増加しており、これらの国々での医薬品需要をさらに増大させています。これとは別に、バイオテクノロジー、免疫学、腫瘍学などの分野で、先進治療のイントロダクションのための広範な研究開発活動への投資が増加していることも、市場の成長を後押ししています。

本レポートで扱う主な質問

  • 世界のファーマジング市場はこれまでどのように推移し、今後数年間はどのように推移するのか？
  • 主要な地域市場は？
  • COVID-19が世界のファーマジング市場に与える影響は？
  • 製品別の市場内訳は？
  • 適応症別の市場内訳は？
  • 流通チャネル別の市場内訳は？
  • 業界のバリューチェーンにおける様々な段階とは？
  • 市場の主な促進要因と課題は何か？
  • 世界のファーマジング市場の構造と主要プレーヤーは？
  • 市場競争の程度は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 世界のファーマジング市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：製品別

  • 医薬品
    • 市場動向
    • 主要タイプ
      • 特許処方薬
      • ジェネリック医薬品
      • 一般用医薬品
    • 市場予測
  • ヘルスケア
    • 市場動向
    • 主な種類
      • 医療機器
      • 臨床診断
      • その他
    • 市場予測

第7章 市場内訳：適応症別

  • 生活習慣病
    • 市場動向
    • 市場予測
  • がんおよび自己免疫疾患
    • 市場動向
    • 市場予測
  • 感染症
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第8章 市場内訳：流通チャネル別

  • 病院
    • 市場動向
    • 市場予測
  • 小売薬局
    • 市場動向
    • 市場予測
  • オンラインストア
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第9章 市場内訳：国別

  • ティアI
    • 中国
      • 市場動向
      • 市場予測
  • ティアII
    • インド
      • 市場動向
      • 市場予測
    • ブラジル
      • 市場動向
      • 市場予測
    • ロシア
      • 市場動向
      • 市場予測
    • 南アフリカ
      • 市場動向
      • 市場予測
  • ティアIII
    • アルゼンチン
      • 市場動向
      • 市場予測
    • メキシコ
      • 市場動向
      • 市場予測
    • ポーランド
      • 市場動向
      • 市場予測
    • ウクライナ
      • 市場動向
      • 市場予測
    • トルコ
      • 市場動向
      • 市場予測
    • サウジアラビア
      • 市場動向
      • 市場予測
    • エジプト
      • 市場動向
      • 市場予測
    • アルジェリア
      • 市場動向
      • 市場予測
    • ナイジェリア
      • 市場動向
      • 市場予測
    • タイ
      • 市場動向
      • 市場予測
    • インドネシア
      • 市場動向
      • 市場予測
    • パキスタン
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Sanofi S.A.
    • Pfizer Inc.
    • AstraZeneca Plc.
    • GlaxoSmithKline Plc.
    • F. Hoffmann-La Roche AG（Roche AG）
    • Eli Lilly and Company
    • Johnson & Johnson
    • Abbott Laboratories
    • Novartis AG
    • Teva Pharmaceutical Limited
図表

List of Figures

  • Figure 1: Global: Pharmerging Market: Major Drivers and Challenges
  • Figure 2: Global: Pharmerging Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Pharmerging Market: Breakup by Product (in %), 2022
  • Figure 4: Global: Pharmerging Market: Breakup by Indication (in %), 2022
  • Figure 5: Global: Pharmerging Market: Breakup by Distribution Channel (in %), 2022
  • Figure 6: Global: Pharmerging Market: Breakup by Country (in %), 2022
  • Figure 7: Global: Pharmerging Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 8: Global: Pharmerging (Pharmaceuticals) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 9: Global: Pharmerging (Pharmaceuticals) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 10: Global: Pharmerging (Healthcare) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 11: Global: Pharmerging (Healthcare) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 12: Global: Pharmerging (Lifestyle Diseases) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 13: Global: Pharmerging (Lifestyle Diseases) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 14: Global: Pharmerging (Cancer and Autoimmune Diseases) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 15: Global: Pharmerging (Cancer and Autoimmune Diseases) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 16: Global: Pharmerging (Infectious Diseases) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 17: Global: Pharmerging (Infectious Diseases) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 18: Global: Pharmerging (Other Indications) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 19: Global: Pharmerging (Other Indications) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 20: Global: Pharmerging (Hospitals) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 21: Global: Pharmerging (Hospitals) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 22: Global: Pharmerging (Retail Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 23: Global: Pharmerging (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 24: Global: Pharmerging (Online Stores) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 25: Global: Pharmerging (Online Stores) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 26: Global: Pharmerging (Other Distribution Channels) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 27: Global: Pharmerging (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 28: Tier I: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 29: Tier I: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 30: China: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 31: China: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 32: Tier II: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 33: Tier II: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 34: India: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 35: India: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 36: Brazil: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 37: Brazil: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 38: Russia: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 39: Russia: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 40: South Africa: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 41: South Africa: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 42: Tier III: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 43: Tier III: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 44: Argentina: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 45: Argentina: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 46: Mexico: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 47: Mexico: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 48: Poland: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 49: Poland: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 50: Ukraine: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 51: Ukraine: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 52: Turkey: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 53: Turkey: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 54: Saudi Arabia: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 55: Saudi Arabia: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 56: Egypt: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 57: Egypt: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 58: Algeria: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 59: Algeria: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 60: Nigeria: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 61: Nigeria: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 62: Thailand: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 63: Thailand: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 64: Indonesia: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 65: Indonesia: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 66: Pakistan: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 67: Pakistan: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 68: Others: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 69: Others: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 70: Global: Pharmerging Industry: SWOT Analysis
  • Figure 71: Global: Pharmerging Industry: Value Chain Analysis
  • Figure 72: Global: Pharmerging Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Pharmerging Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Pharmerging Market Forecast: Breakup by Product (in Million US$), 2023-2028
  • Table 3: Global: Pharmerging Market Forecast: Breakup by Indication (in Million US$), 2023-2028
  • Table 4: Global: Pharmerging Market Forecast: Breakup by Distribution Channel (in Million US$), 2023-2028
  • Table 5: Global: Pharmerging Market Forecast: Breakup by Country (in Million US$), 2023-2028
  • Table 6: Global: Pharmerging Market: Competitive Structure
  • Table 7: Global: Pharmerging Market: Key Players
目次
Product Code: SR112023A3441

Abstract

The global pharmerging market size reached US$ 1.1 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 2.2 Billion by 2028, exhibiting a growth rate (CAGR) of 12.2% during 2022-2028.

Pharmerging refers to a group of countries that hold low positioning in the pharmaceutical market but have a speedy growth. Some of the key pharmerging markets include China, India, Brazil, Russia, South Africa, Mexico, Indonesia, Turkey, etc.

The increasing healthcare expenditures along with the rising number of private hospitals are currently propelling the global pharmerging market growth. Additionally, the high prevalence of numerous chronic diseases and growing consumer awareness towards early disease detection and treatment procedures are further augmenting the market growth. Moreover, the increasing geriatric population, who are more prone to serious medical conditions, such as dementia, hypertension, cardiac failure, etc., is also bolstering the demand for pharmaceuticals. Additionally, the introduction of government policies and reimbursement schemes across various countries for reducing the cost of treatment for chronic diseases is also propelling the market growth. Moreover, the growing number of insurance companies in the pharmerging countries offering numerous insurance policies to decrease the out-of-the-pocket expenditures is further augmenting the demand of pharmaceuticals in these countries. Apart from this, the rising investments in extensive R&D activities in the fields of biotechnology, immunology, oncology, etc., for the introduction of advanced treatments are also catalyzing the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global pharmerging market report, along with forecasts at the global and country level from 2023-2028. Our report has categorized the market based on product, indication and distribution channel.

Breakup by Product:

Pharmaceuticals

Patented Prescription Drugs

Generic Prescription Drugs

OTC Drugs

Healthcare

Medical Devices

Clinical Diagnosis

Others

Breakup by Indication:

Lifestyle Diseases

Cancer and Autoimmune Diseases

Infectious Diseases

Others

Breakup by Distribution Channel:

Hospitals

Retail Pharmacies

Online Stores

Others

Breakup by Country:

Tier I

China

Tier II

India

Brazil

Russia

South Africa

Tier III

Argentina

Mexico

Poland

Ukraine

Turkey

Saudi Arabia

Egypt

Algeria

Nigeria

Thailand

Indonesia

Pakistan

Others

Competitive Landscape:

The competitive landscape of the industry has also been examined with some of the key players being Sanofi S.A., Pfizer Inc., AstraZeneca Plc, GlaxoSmithKline Plc, F. Hoffmann-La Roche AG (Roche AG), Eli Lilly and Company, Johnson & Johnson, Abbott Laboratories, Novartis AG and Teva Pharmaceutical Limited.

Key Questions Answered in This Report:

  • How has the global pharmerging market performed so far and how will it perform in the coming years?
  • What are the key regional markets?
  • What is the impact of COVID-19 on the global pharmerging market?
  • What is the breakup of the market based on the product?
  • What is the breakup of the market based on the indication?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the market?
  • What is the structure of the global pharmerging market and who are the key players?
  • What is the degree of competition in the market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Pharmerging Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Pharmaceutical
    • 6.1.1 Market Trends
    • 6.1.2 Major Types
      • 6.1.2.1 Patented Prescription Drugs
      • 6.1.2.2 Generic Prescription Drugs
      • 6.1.2.3 OTC Drugs
    • 6.1.3 Market Forecast
  • 6.2 Healthcare
    • 6.2.1 Market Trends
    • 6.2.2 Major Types
      • 6.2.2.1 Medical Devices
      • 6.2.2.2 Clinical Diagnosis
      • 6.2.2.3 Others
    • 6.2.3 Market Forecast

7 Market Breakup by Indication

  • 7.1 Lifestyle Diseases
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Cancer and Autoimmune Diseases
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Infectious Diseases
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Retail Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Stores
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Country

  • 9.1 Tier I
    • 9.1.1 China
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
  • 9.2 Tier II
    • 9.2.1 India
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Brazil
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 Russia
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Africa
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
  • 9.3 Tier III
    • 9.3.1 Argentina
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 Mexico
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 Poland
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Ukraine
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Turkey
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Saudi Arabia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Egypt
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
    • 9.3.8 Algeria
      • 9.3.8.1 Market Trends
      • 9.3.8.2 Market Forecast
    • 9.3.9 Nigeria
      • 9.3.9.1 Market Trends
      • 9.3.9.2 Market Forecast
    • 9.3.10 Thailand
      • 9.3.10.1 Market Trends
      • 9.3.10.2 Market Forecast
    • 9.3.11 Indonesia
      • 9.3.11.1 Market Trends
      • 9.3.11.2 Market Forecast
    • 9.3.12 Pakistan
      • 9.3.12.1 Market Trends
      • 9.3.12.2 Market Forecast
    • 9.3.13 Others
      • 9.3.13.1 Market Trends
      • 9.3.13.2 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Sanofi S.A.
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 Pfizer Inc.
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 AstraZeneca Plc.
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 GlaxoSmithKline Plc.
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 F. Hoffmann-La Roche AG (Roche AG)
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
      • 13.3.5.4 SWOT Analysis
    • 13.3.6 Eli Lilly and Company
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7 Johnson & Johnson
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8 Abbott Laboratories
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
      • 13.3.8.4 SWOT Analysis
    • 13.3.9 Novartis AG
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis
    • 13.3.10 Teva Pharmaceutical Limited
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financial
      • 13.3.10.4 SWOT Analysis